Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aims to tame rare blood vessel disease

NCT ID NCT06388941

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding the oral drug iptacopan to standard therapy (rituximab) helps people with active ANCA vasculitis achieve and maintain remission. About 84 adults with newly diagnosed or relapsed disease will receive either iptacopan or a placebo, plus standard care. The study tracks remission rates, kidney function, and quality of life over 48 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Iptacopan (also called LNP023), a pill taken by mouth

What this could lead to

If it works, this could offer a new treatment option for ANCA vasculitis that helps patients reach and stay in remission with fewer steroid-related side effects.

What could go wrong

This is a mid-stage trial with only 84 participants, so results may not apply to everyone. The drug may not improve remission rates or could cause unexpected side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTI-NEUTROPHIL CYTOPLASM ANTIBODIES (ANCA) ASSOCIATED VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anti-neutrophil cytoplasmic antibody-associated vasculitis granulomatosis with polyangiitis microscopic polyangiitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTI-NEUTROPHIL CYTOPLASM ANTIBODIES (ANCA) ASSOCIATED VASCULITIS

Contacts and locations

Locations

  • Arizona Arthritis and Rheumatology Research PLLC

    Mesa, Arizona, 85202, United States

  • Mayo Clinic Rochester

    Rochester, Minnesota, 55905, United States

  • Novartis Investigative Site

    CABA, Buenos Aires, C1180AAX, Argentina

  • Novartis Investigative Site

    La Plata, Buenos Aires, B1900AWT, Argentina

  • Novartis Investigative Site

    CABA, C1181ACH, Argentina

  • Novartis Investigative Site

    Concord, New South Wales, 2139, Australia

  • Novartis Investigative Site

    Clayton, Victoria, 3168, Australia

  • Novartis Investigative Site

    Innsbruck, Tyrol, 6020, Austria

  • Novartis Investigative Site

    Graz, 8036, Austria

  • Novartis Investigative Site

    Vienna, 1090, Austria

  • Novartis Investigative Site

    Leuven, Vlaams Brabant, 3000, Belgium

  • Novartis Investigative Site

    Roeselare, West-Vlaanderen, 8800, Belgium

  • Novartis Investigative Site

    London, Ontario, N6A 5W9, Canada

  • Novartis Investigative Site

    Fleurimont, Quebec, J1H 5N4, Canada

  • Novartis Investigative Site

    Montreal, Quebec, H2X 1R9, Canada

  • Novartis Investigative Site

    Montreal, Quebec, H4J 1C5, Canada

  • Novartis Investigative Site

    Québec, Quebec, G1R 2J6, Canada

  • Novartis Investigative Site

    Shijiazhuang, Hebei, 050000, China

  • Novartis Investigative Site

    Zhengzhou, Henan, 450003, China

  • Novartis Investigative Site

    Beijing, 100034, China

  • Novartis Investigative Site

    Prague, 128 08, Czechia

  • Novartis Investigative Site

    Aarhus N, 8200, Denmark

  • Novartis Investigative Site

    Herlev, DK-2730, Denmark

  • Novartis Investigative Site

    Angers, 49933, France

  • Novartis Investigative Site

    Brest, 29200, France

  • Novartis Investigative Site

    Dijon, 21000, France

  • Novartis Investigative Site

    Marseille, 13005, France

  • Novartis Investigative Site

    Paris, 75014, France

  • Novartis Investigative Site

    Toulouse, 31054, France

  • Novartis Investigative Site

    Kirchheim unter Teck, Baden-Wurttemberg, 73230, Germany

  • Novartis Investigative Site

    Munich, Bavaria, 81377, Germany

  • Novartis Investigative Site

    Berlin, 13353, Germany

  • Novartis Investigative Site

    Ludwigshafen, 67063, Germany

  • Novartis Investigative Site

    Mainz, 55131, Germany

  • Novartis Investigative Site

    Budapest, H-1083, Hungary

  • Novartis Investigative Site

    Szeged, 6725, Hungary

  • Novartis Investigative Site

    Plasencia, Caceres, 10600, Spain

  • Novartis Investigative Site

    Pamplona, Navarre, 31008, Spain

  • Novartis Investigative Site

    Madrid, 28046, Spain

  • Novartis Investigative Site

    Istanbul, Pendik, 34899, Turkey (Türkiye)

  • Novartis Investigative Site

    Ankara, Sihhiye-Altindag, 06230, Turkey (Türkiye)

  • Novartis Investigative Site

    Cambridge, CB2 0QQ, United Kingdom